Exelixis, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| 0IJO.L | HCM | 688266.SS | RCUS | 2410.HK | 300558.SZ | |
|---|---|---|---|---|---|---|
| Market cap | — | 2.46B | 24.15B | 2.34B | 1.21B | 20.76B |
| P/E (TTM) | 79.1 | 141.8 | 42.6 | — | — | 77.9 |
| Forward P/E | — | 54.7 | 73.0 | -6.0 | -6.1 | 29.2 |
| Price/book | 9.8 | 2.0 | 14.1 | 3.7 | 4.0 | 3.2 |
| Dividend yield | — | — | — | — | — | 0.31% |
| 1-year change | +87.10% | −9.90% | −8.21% | −1.28% | −80.24% | −11.61% |
| Today | +3.07% | +1.87% | +0.12% | −3.73% | +9.61% | +1.62% |
The closest companies by business. Prices may be delayed up to 15 min.
Latest news
All 0IJO.L news ›Exelixis outlines March 3, 2027 PDUFA for zanza while advancing Wave 2 pivotal plans
Exelixis Q3 2026 earnings: CABOMETYX growth, zanzalintinib pipeline milestones, and key 2027 catalysts. Earnings Call Insights: Exelixis (EXEL) Q3 2026 - Michael Morrissey framed zanzalintinib as the next growth driver, saying,…
Exelixis (NASDAQ:EXEL) Stock Price Expected to Rise, TD Cowen Analyst Says
Posted by Tristan Rich on Oct 30th, 2026 Exelixis (NASDAQ:EXEL – Get Free Report) had its target price boosted by equities researchers at TD Cowen from $55.00 to $76.00 in a report issued on Friday, Benzinga reports. The firm currently has…
Exelixis, Inc. (EXEL) Q3 2026 Earnings Call Transcript
Exelixis, Inc. (EXEL) Q3 2026 Earnings Call October 29, 2026 5:00 PM EDT Andrew Peters - Senior Vice President of StrategyMichael Morrissey - CEO, President & DirectorChristopher Senner - Executive VP & CFODana Aftab - Executive Vice…
Exelixis Announces Third Quarter 2026 Financial Results and Provides Corporate Update
– Total Revenues of $658.7 million, Cabozantinib Franchise U.S. Net Product Revenues of $604.9 million – – GAAP Diluted EPS of $0.85, Non-GAAP Diluted EPS of $0.94 – – Conference Call and Webcast Today at 5:00 PM ET – ALAMEDA,…
Forget the FDA Delay: 3 Reasons Exelixis Is Still a Buy
It has also continued to grind out new indications, including as a combination therapy. Exelixis' financial results have been strong thanks to this drug. In the second quarter, the company's revenue increased by 10.6% year over year to…
Exelixis, Inc. (NASDAQ:EXEL) Stock Has Consensus Target Price of $50.79 According to Brokerages
Posted by Danessa Lincoln on Oct 17th, 2026 Get Our Latest Research Report on Exelixis Exelixis, Inc is a biopharmaceutical company focused on discovering, developing, and commercializing medicines for cancer. The company’s research and…
Exelixis to Release Third Quarter 2026 Financial Results on Thursday, October 29, 2026
Investing News Network Exelixis to Release Third Quarter 2026 Financial Results on Thursday, October 29, 2026 Conference Call and Webcast to Follow at 5:00 p.m. ET 2:00 p.m. PT – Exelixis, Inc. (Nasdaq: EXEL) an
Kuehn Law Encourages Investors of EXELIXIS, Inc. to Contact Law Firm
PR Newswire NEW YORK, Oct. 12, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of EXELIXIS, Inc. (NASDAQ: EXEL) breached their fiduciary duties to sha
Bank of America Securities Sticks to Its Sell Rating for Exelixis (EXEL)
In a report released today, Jason Gerberry from Bank of America Securities maintained a Sell rating on Exelixis, with a price target of $41.00. According to TipRanks, Gerberry is a 5-star analyst with an average return of 18.5% and a…
FDA Extends Review of Exelixis' Zanzalintinib in Colorectal Cancer
Published on 09/11/2026 at 07:51 am EDT Exelixis said the Food and Drug Administration has extended its review of the company's proposed zanzalintinib cancer drug by three months. Exelixis, which is seeking FDA approval zanzalintinib in…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- seekingalpha.com5
- themarketsdaily.com3
- marketscreener.com2
- biospace.com1
- fool.com1
Finance and business coverage in the 4Search news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 18 articles, not a forecast.